Abstract
Particularly expressed in the kidney, αKlotho is a transmembrane protein that acts together with bone hormone fibroblast growth factor 23 (FGF23) to regulate renal phosphate and vitamin D homeostasis. Soluble Klotho (sKL) is released from the transmembrane form and controls various cellular functions as a paracrine and endocrine factor. αKlotho deficiency accelerates aging, whereas its overexpression favors longevity. Higher αKlotho abundance confers a better prognosis in cardiovascular and renal disease owing to anti-inflammatory, antifibrotic, or antioxidant effects and tumor suppression. Serine/threonine protein kinase C (PKC) is ubiquitously expressed, affects several cellular responses, and is also implicated in heart or kidney disease as well as cancer. We explored whether PKC is a regulator of αKlotho. Experiments were performed in renal MDCK or NRK-52E cells and PKC isoform and αKlotho expression determined by qRT-PCR and Western Blotting. In both cell lines, PKC activation with phorbol ester phorbol-12-myristate-13-acetate (PMA) downregulated, while PKC inhibitor staurosporine enhanced αKlotho mRNA abundance. Further experiments with PKC inhibitor Gö6976 and RNA interference suggested that PKCγ is the major isoform for the regulation of αKlotho gene expression in the two cell lines. In conclusion, PKC is a negative regulator of αKlotho gene expression, an effect which may be relevant for the unfavorable effect of PKC on heart or kidney disease and tumorigenesis.
Similar content being viewed by others
Introduction
αKlotho is mainly expressed in the kidney as a transmembrane protein [33, 36]. On the one hand, it enhances affinity of fibroblast growth factor 23 (FGF23) for fibroblast growth factor receptor (FGFR) proteins, thereby functioning as a co-receptor [59]. FGF23 is a hormone predominantly produced by bone cells under physiological conditions that is a major regulator of vitamin D and phosphate homeostasis [53] along with other hormonal regulators of Ca2+ and phosphate metabolism, especially 1,25(OH)2D3 (biologically active vitamin D) and parathyroid hormone [3, 5, 20]. The joint action of FGF23 and its co-receptor αKlotho results in a decrease of membrane abundance of NaPi-IIa, the major Na+-dependent phosphate transporter of the renal proximal tubule [23], and in lower expression of 1α-hydroxylase, the key enzyme for the synthesis of 1,25(OH)2D3 in the kidney and in other cells [1, 51]. Hence, FGF23 along with αKlotho lowers the blood levels of both, phosphate and 1,25(OH)2D3 [54].
Apart from transmembrane αKlotho, a circulating form of this protein exists named soluble Klotho (sKL). SKL has paracrine and endocrine effects on various cells including the regulation of ion transport or significant signaling pathways such as Wnt or phosphoinositide-3-kinase (PI3K) signaling [29, 63, 75].
Lack of either αKlotho or FGF23 leads to a strong phenotype in mice that reminds of aging of human beings: The animals exhibit aging-related disorders of most organs and tissues and die prematurely [37, 55]. Above all, organs and tissues are affected by strong calcification [69] that can be prevented if the animals are fed a low vitamin D- or low phosphate diet [8, 46]. Hence, premature aging in αKlotho or FGF23 deficiency is dependent on deranged phosphate metabolism [32, 49].
Conversely, mice have a strongly expanded life span if αKlotho is overexpressed, a finding corroborating the role of αKlotho as an antiaging factor [37].
In addition, αKlotho has been demonstrated to have beneficial effects on multiple organs and to favorably influence a broad range of diseases: It is cardio- or nephroprotective [4, 19, 72], it provides protection from neurodegeneration, it exerts anti-inflammatory, antifibrotic, and antioxidant effects, and it has turned out to be a tumor suppressor [43, 44, 73, 74, 77]. Hence, lower αKlotho levels result in a poorer prognosis of cardiovascular or renal diseases as well as different human malignancies [14, 42, 68]. Also, FGF23 is a marker of kidney function [9, 26] or cardiovascular disease [12] with higher FGF23 levels predicting worse outcome.
Protein kinase C (PKC) is expressed in every cell and among the major regulators of most cellular functions and responses [10]. It is a serine/threonine kinase and classically activated by Ca2+ and diacylglycerol (DAG) that is released from the membrane in response to phospholipase C activation by Gq protein-coupled receptors or receptor tyrosine kinases (classical PKC) [31, 58]. Novel PKC isoforms are activated by DAG only whereas atypical PKC isoforms depend on other mechanisms for activation [28].
On a cellular level, PKC is a regulator of proliferation, migration, and apoptosis [16, 52]. Similar to αKlotho, PKC isoforms are implicated in neurodegeneration and different human diseases [27]. PKC is a regulator of FGF23 [2, 22]. Whereas αKlotho is a tumor suppressor, PKC rather promotes tumorigenesis [25]. PKC is also relevant for kidney disease including diabetic nephropathy [64] and various heart diseases [57].
Since αKlotho and PKC are relevant for similar pathologies and are often characterized by opposing effects, we wondered whether PKC is a regulator of αKlotho expression. We therefore performed experiments in Madin-Darby canine kidney (MDCK) and normal rat kidney (NRK-52E) cells to elucidate the effect of PKC on αKlotho and to identify the PKC isoform involved.
Methods
Cell culture
MDCK (NBL-2) cells (CVCL_0422; Cell Lines Services, Eppelheim, Germany) were cultured in Dulbecco’s modified Eagle medium F12 (DMEM/F-12; Gibco, Life Technologies, Darmstadt, Germany) with additional 5% fetal bovine serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco), and 2 mM glutamine (Gibco). NRK-52E cells (ECACC 87012902; European Collection of Authenticated Cell Cultures, Salisbury, UK) were cultured in Dulbecco’s modified Eagle medium (DMEM) plus 5% newborn calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco). For experiments, cells were plated at a density of 1.5×105 cells per well (MDCK) or 2×105 cells per well (NRK-52E) in 6-well plates at 5% CO2 and 37°C. After 24 h, cells were treated with PKC activator phorbol-12-myristate-13-acetate (PMA) (0.01–600 nM as indicated; Peprotech, Hamburg, Germany) and/or PKC inhibitors staurosporine (0.01–1 nM as indicated; Cayman Chemicals, Ann Arbor, MI, USA), 300 nM sotrastaurine (United States Biological, Salem, MA, USA), or 40 nM Gö6976 (Biomol, Hamburg, Germany) for further 24 h. Control cells were incubated with the respective amount of solvent dimethyl sulfoxide (DMSO; AppliChem, Darmstadt, Germany) for all experiments.
Silencing
MDCK cells (1.2×105 per well) were cultured for 24 h in complete growth medium. Cells were then transfected with custom-designed PKCγ small interfering RNA (siRNA) (25 nM; sense: ACAAGUUACUGAACCAGGAtt, antisense: UCCUGGUUCAGUAACUUGUAC, Invitrogen, Thermo Fisher Scientific, Darmstadt, Germany), custom-designed PKCη siRNA (25 nM; sense: GAAAUGGGAUCGGAGUUAAtt, antisense: UUAACUCCGAUCCCAUUUCcc, Invitrogen) or 25 nM non-targeting control siRNA (#4390843, Invitrogen) using 5-μl Lipofectamine RNAiMAX (Invitrogen) transfection reagent in antibiotic-free complete medium for 24 h. For silencing of NRK-52E cells, 1.5×105 cells per well were grown in complete medium for 24 h and then transfected with custom-designed PKCγ siRNA (50 nM; sense: ACAAGUUACUGAACCAGGAtt, antisense: UCCUGGUUCAGUAACUUGUAC, Invitrogen) or 50 nM non-targeting control siRNA (#4390843, Invitrogen) using 5 μl DharmaFECT 1 (Horizon Discovery, Cambridge, UK) transfection reagent in antibiotic-free complete medium for 24 h. Silencing efficiency was determined by quantitative real-time PCR.
Quantitative real-time PCR (qRT-PCR)
Cells were washed with ice-cold PBS and total RNA was isolated using TriFast (Peqlab, Erlangen, Germany). Isolates from MDCK cells were subjected to DNase digestion and RNA was extracted using NucleoSpin RNA Mini kit (Macherey-Nagel, Düren, Germany). Total RNA (1.2 μg; 60 ng/μl) was taken for cDNA synthesis with random primers and the GoScript Reverse Transcription System (both from Promega, Mannheim, Germany). Quantitative RT-PCR was performed on a CFX Connect Real Time System (Bio-Rad Laboratories, Feldkirchen, Germany) utilizing GoTaq qPCR Master Mix (Promega). Conditions were: 95°C for 5 min; followed by 40 cycles of 95°C for 10 s, annealing at primer-specific temperature for 30 s, and 72°C for 30 s. The final volume of the qRT-PCR master mix was 20 μl comprising 2 μl cDNA, 0.5 μM (or 0.25 μM for rat and dog αKlotho) forward and reverse primer, and water. Primer sequences are listed in Table 1.
Calculated mRNA expression levels were normalized to TATA box-binding protein (TBP) transcript levels. TBP mRNA expression was not significantly affected by either treatment. Relative quantification of target gene expression was accomplished by the 2−ΔCT method.
For qualitative mRNA expression analysis of PKC isoforms in MDCK cells, a minus reverse transcriptase (−RT) control was included in all qRT-PCR assays. About 10 μl of the qRT-PCR product as well as non-template control and −RT control were loaded onto a 1.5% ethidium bromide agarose gel. Bands were visualized by UV spectrometry (BioDocAnalyzer, Biometra, Göttingen, Germany).
Cell viability assay
Cell viability was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were cultured for 24 h and then exposed to 1 nM staurosporine or vehicle for another 24 h. Next, cells were incubated with 0.5 mg/ml MTT solution (Sigma-Aldrich, Schnelldorf, Germany) for 1 h followed by MTT solution removal and addition of DMSO. Absorbance was measured at 550 nm (reference wavelength 650 nm) by using a microplate reader (FLUOstar Omega; BMG Labtech, Ortenberg, Germany). Cell viability of staurosporine-treated cells was expressed as the percentage of cell viability of vehicle-treated cells.
Western Blotting
MDCK and NRK-52E cells were seeded into 6-well plates or T25 cell culture flasks (Greiner Bio-One, Frickenhausen, Germany) for 24 h under standard cell culture conditions. Next, cells were treated with PMA (30 nM, 24 h), non-targeting or custom-designed PKCγ siRNA (25 nM, 72 h), staurosporine (1 nM, 24 h), or vehicle only. Cells were lysed using ice-cold RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) supplemented with protease and phosphatase inhibitor cocktail and EDTA (Halt, Thermo Fisher Scientific), and proteins (30 or 50 μg) were subjected to 10 or 12% SDS-PAGE and standard Western Blotting. The following antibodies were used: anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (#D13.14.4E), anti-p44/42 MAPK (Erk1/2) (#9102), anti-GAPDH (#D16H11) (all three from Cell Signaling Technology), clone KM2076 anti-Klotho (#SCE-KO603; Hölzel Diagnostika, Cologne, Germany), anti-PKC gamma (#PA5-28618; Invitrogen, Thermo Fisher Scientific), anti-rabbit IgG HRP-linked (Cell Signaling Technology), and anti-goat IgG HRP-linked antibody (Sigma-Aldrich). Finally, proteins were visualized using Clarity Western (Bio-Rad Laboratories) or Westar Hypernova (Cyanagen, Bologna, Italy) ECL substrate. Bands were detected by ChemiDoc MP Imaging System (Bio-Rad Laboratories) and signal intensities were determined using Image Lab Software (Version 6.1, Bio-Rad Laboratories). Data are shown as ratio of target protein to loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or phosphorylated protein to total protein, normalized to control.
Statistics
Data are shown as scatter dot plots and arithmetic means ± standard deviation (SD), with n indicating the number of independent cell culture experiments. All data were tested for normality (Shapiro Wilk and Kolmogorov-Smirnov test). Statistical comparisons of two groups were made by two-tailed paired Student’s t-test or Wilcoxon matched-pairs signed rank test (for data not passing normality). For more than two groups, nonparametric Friedman test followed by Dunn’s multiple comparison test or repeated measures two-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test was applied as indicated in the figure legends. Only results with p < 0.05 were considered statistically significant. Statistical analyses were performed using GraphPad Prism 10 (version 10.0.0; GraphPad Software Inc., San Diego, CA, USA).
It was necessary to evaluate the measurements using paired tests, since they were made at different points in time and time-fixed effects are not considered. Therefore, each measurement should be treated as a group consisting of a single observation without the possibility of assuming homogeneity between groups. Consequently, there is a clear one-to-one pairing between the observations in the control and treatment groups across the entire set of observations, through the grouping that results from measuring at different times when different, uncontrollable conditions may prevail. Further, it is not possible to use unpaired testing procedures that aggregate the control and treatment group into a single representative statistic to infer on the characteristics of the sample because of non-negligible time series properties due to the design of the experiment. Aggregation may not be meaningful due to the underlying processes affecting the level of the parameters determined in the control and treatment group samples pre-treatment.
Results
We performed experiments in MDCK and NRK-52E cells in order to investigate whether PKC activity influences αKlotho gene expression. First, we verified the qualitative expression of different PKC isoforms in MDCK cells. According to Fig. 1a, MDCK cells expressed PKCα, PKCγ, PKCδ, PKCε, PKCζ, PKCη, PKCθ, and PKCι. After this qualitative approach, we also performed qRT-PCR analysis to compare relative expression levels of PKC isoforms in MDCK cells (Fig. 1b) and NRK-52E cells (Fig. 1c).
Since phorbol esters are potent stimulators of PKC, we treated the cells for 24 h with increasing concentrations of PMA and utilized qRT-PCR to quantify αKlotho transcripts [60]. As illustrated in Fig. 2a, at a dose as low as 30 nM, PMA significantly reduced transcripts specific for αKlotho in MDCK cells, an effect, even more pronounced at higher concentrations of PMA. In order to investigate whether PMA treatment indeed resulted in PKC activation, we determined phosphorylation of ERK1/2 by Western Blotting [65]. As demonstrated in Fig. 2b and suppl. Fig. 1, PMA readily upregulated phospho-ERK1/2 protein abundance, an effect in line with PKC activation. Next, we aimed to inhibit PKC activity in MDCK cells by using low concentrations of staurosporine, which may also inhibit other kinases at higher concentrations, but which has the lowest IC50 value for PKC of 2.7 nM [61]. Figure 2c shows that 1 nM staurosporine significantly enhanced αKlotho gene expression in MDCK cells. Treatment with 1 nM staurosporine for 24 h resulted in a moderate but significant reduction of cell viability (Fig. 2d). Another series of experiments explored whether PKC stimulation with PMA is ineffective in the presence of staurosporine. As demonstrated in Fig. 2e, PMA alone downregulated αKlotho in MDCK cells again even at a concentration as low as 100 pM in a new series of experiments, an effect, significantly blunted in the presence of staurosporine. However, even in the presence of staurosporine, PMA significantly downregulated αKlotho (Fig. 2e).
Next, we used NRK-52E cells to test whether PKC activity also modulates αKlotho expression in another kidney cell line. We treated these cells with PMA and found that ≥ 100 nM PMA significantly suppressed αKlotho gene expression (Fig. 3a). Similar to MDCK cells, PKC inhibition with staurosporine upregulated αKlotho mRNA abundance in NRK-52E cells, an effect reaching statistical significance at a concentration of staurosporine as low as 100 pM (Fig. 3b). Since Western Blotting did not work in canine MDCK cells, we performed Western Blotting of rat NRK-52E cell lysates in order to study whether the staurosporine effect on αKlotho gene expression also translates into higher αKlotho protein expression. As illustrated in Fig. 3c, Western Blotting of NRK-52E cell lysate using a primary anti-αKlotho antibody yielded a band in the range of 110–120 kDa that we used for quantification (Fig. 3c, lower panel). A similar band was detected using the same antibody in a mouse kidney [67] or another anti-αKlotho antibody in NRK-52E cells [76]. In a further series of experiments, PMA again downregulated and staurosporine upregulated αKlotho expression in NRK-52E cells (Fig. 3d). The combined treatment with PMA and staurosporine resulted in αKlotho expression levels not significantly different from control (Fig. 3d).
Staurosporine is mainly an inhibitor of PKCα, PKCγ, and PKCη [41, 70]. In order to identify the PKC isoform accounting for the effect on αKlotho, we performed further experiments in MDCK cells with sotrastaurine inhibiting PKCα, PKCβ, PKCδ, PKCε, PKCη, and PKCθ, as well as with Gö6976, an inhibitor of PKCα and PKCβ. Treatment with sotrastaurine (Fig. 4a) or Gö6976 (Fig. 4b), however, failed to significantly affect αKlotho transcripts.
Our experiments with sotrastaurine and Gö6976 prompted us to consider PKCγ as the major isoform accounting for the PKC effect on αKlotho transcripts although this isoform has thus far been thought to be mostly if not exclusively expressed in neurons [56]. As a first step, we analyzed PKCγ gene expression. As detailed in Fig. 5a, both, MDCK and NRK-52E cells, expressed mRNA specific for PKCγ, a finding verified by sequencing. Next, we performed Western Blotting to detect PKCγ protein abundance in the two cell lines. According to Fig. 5b, MDCK and NRK-52E cells exhibited a low but detectable protein expression of PKCγ. High levels of PKCγ were found in the brain and virtually no expression found in the kidney (Fig. 5b). Next, we employed RNA interference (RNAi) to silence PKCγ. According to Fig. 5c, siRNA specific for PKCγ significantly downregulated PKCγ expression in MDCK cells compared to nonsense siRNA. Also on protein level, exposure of MDCK cells to specific siRNA targeting PKCγ was paralleled by downregulation of PKCγ (Fig. 5d). Importantly, the effect was paralleled by upregulation of αKlotho gene expression (Fig. 5e). In cells treated with PKCγ-specific siRNA, the PMA effect on αKlotho was lower (p=0.052) than in cells treated with nonsense siRNA although PMA was still capable of suppressing αKlotho upon PKCγ silencing (Fig. 5e). Similarly, PKCγ-specific siRNA significantly downregulated PKCγ expression in NRK-52E cells (Fig. 5f) and increased the abundance of αKlotho expression (Fig. 5g). Another siRNA specifically targeting PKCγ yielded similar results in NRK-52E cells (suppl. Fig. 2).
To investigate whether isoform PKCη might also be involved, we performed further RNAi experiments. SiRNA-mediated downregulation of PKCη resulted in significantly lower PKCη expression in MDCK cells (Fig. 6a), but did not significantly affect αKlotho gene expression (Fig. 6b).
Discussion
According to our study, PKC is a negative regulator of αKlotho gene expression in both, MDCK and NRK-52E cells. Hence, PKC activator PMA reduced αKlotho mRNA abundance in both cell lines.
Whereas our study revealed an effect of PKC signaling on αKlotho at least in vitro, a stimulatory effect of αKlotho on PKC activity in the kidney (and in the testis) was reported much earlier [24]. According to this study, Klotho induced PKC signaling exclusively in the kidney and testis (organs with high Klotho expression) and downregulated 25-hydroxyvitamin D3 1α-hydroxylase, the key enzyme for renal 1,25(OH)2D3 production although PKC signaling directly induces 25-hydroxyvitamin D3 1α-hydroxylase expression [24]. Together, these findings may suggest that Klotho and PKC signaling amplify each other in the kidney.
For our cell culture experiments, we took benefit from the varying inhibitory potentials for different PKC isoforms [31]. Staurosporine which has the lowest IC50 values for PKCα, PKCγ, and PKCη [41] turned out to be a potent enhancer of αKlotho expression. According to this result, it appears to be likely that the isoform most relevant for the effect is among the three. Since PKCα and PKCβ inhibitor Gö6976 and sotrastaurine inhibiting PKCα, PKCβ, PKCδ, PKCε, PKCη, and PKCθ failed to significantly affect αKlotho, we hypothesized that PKCγ is the isoform downregulating αKlotho in MDCK and NRK-52E cells. Our experiments with two different siRNAs specific for PKCγ and one for PKCη confirmed this assumption. However, we cannot rule out that isoforms other than PKCγ also impact αKlotho gene expression. This holds true in particular since PMA was still capable of significantly downregulating αKlotho in the presence of PKCγ-specific siRNA, although the PMA effect was reduced (p=0.052) in PKCγ-silenced cells compared to control cells. This may be due to the fact that silencing does not completely abrogate PKCγ activity or that other PKC isoforms also contribute to the PMA effect on αKlotho.
The seemingly dominant role of PKCγ for αKlotho expression in renal MDCK and NRK-52E cells comes as a surprise as PKCγ is thought to be mainly if not exclusively expressed in neurons [56]. In line with this, our Western Blotting analysis revealed a much stronger band for PKCγ in the brain than in MDCK and NRK-52E cells. However, PKCγ protein expression was detectable in MDCK and NRK-52E cells, and sequencing confirmed that both cell lines do express PKCγ mRNA. Moreover, two different siRNAs specifically targeting PKCγ yielded similar results on αKlotho expression in NRK-52E cells. Therefore, it appears to be safe to conclude that PKCγ contributes to αKlotho regulation in these renal cell lines. In the kidney, however, we detected no PKCγ expression, a finding in line with the literature according to which all PKC isoforms but PKCγ and PKCθ are expressed in the kidney [39]. A recent study, however, found strong PKCγ immunoreactivity in the proximal tubule of the developing and very weak immunoreactivity in the proximal tubule of the adult kidney [30]. Hence, it appears likely that a PKC isoform other than PKCγ is relevant for αKlotho regulation in the kidney although a role for PKCγ, at least in certain developing stages, cannot totally be ruled out. Clearly, our study suggests that care must be taken when extrapolating cell culture results to the organism.
Staurosporine is a cytotoxic agent, and treatment with staurosporine resulted in moderate reduction of viability of MDCK cells. Since reduced cell viability due to cytotoxicity has been demonstrated to ramp up αKlotho expression [47], it appears to be possible that this effect is also relevant, at least in part, for staurosporine-dependent upregulation of αKlotho. Therefore, staurosporine may also be effective independent of PKC activity. Whether these in vitro effects play a role in vivo needs to be shown. PKC-dependent gene expression is known to involve ERK, JNK/AP1, NF-κB, or JAK/STAT signaling [7]. Our study did not address the downstream signaling of the PKC effect on αKlotho. Further studies are therefore needed to elucidate whether these or other PKC-dependent pathways mediate the effect on αKlotho expression.
By Western Blotting, we could confirm in rat NRK-52E cells that PKC inhibition with staurosporine also upregulates αKlotho protein.
The regulation of αKlotho is potentially of high clinical interest since αKlotho has been revealed to exert multiple beneficial effects on a cellular level and in animal models of disease: It confers anti-inflammatory, antioxidant, antifibrotic, and tumor suppressing actions and is cardioprotective and nephroprotective or improves endothelial function [4, 14, 18, 63, 66, 71]. Not surprisingly, higher αKlotho levels are associated with better outcome in rodent models of kidney disease [40]. In human association studies, higher sKL levels are linked to better prognosis in kidney and cardiovascular disease and several malignancies [13, 15, 17, 34, 35, 50]. Therefore, enhancement of endogenous αKlotho production may be a novel and attractive therapeutic approach for those and other diseases, and therefore, a better understanding of αKlotho gene expression regulation is warranted. Our study adds to this understanding by revealing PKC as a negative regulator of αKlotho gene expression.
In line with beneficial effects of higher αKlotho availability, PKC activity is a driver of kidney disease, in particular of diabetic nephropathy, which is among the leading causes for declining kidney function ultimately resulting in end-stage renal disease [48]. Hence, PKC inhibition is beneficial in this condition [39]. Importantly, diabetic nephropathy is associated with early loss of αKlotho, and higher αKlotho levels improve the prognosis [38, 66]. Our finding, i.e., upregulation of αKlotho following PKC inhibition may contribute to the beneficial effects of this approach in diabetic nephropathy. Similarly, PKC activation has been attributed to drive pathological processes in the failing heart with different isoforms being involved [6, 57]. Also in heart disease, αKlotho is advantageous, at least in part due to its antioxidant and antifibrotic effects, and it is tempting to speculate that PKC-dependent downregulation of αKlotho as revealed by our study may, at least in part, account for unfavorable effects of PKC in heart disease [62, 72].
It must be considered, however, that therapeutic PKC inhibition may be limited by its toxicity: Staurosporine may induce neuronal death [11], and its therapeutic suitability may therefore be low. In contrast, midostaurin, another PKC inhibitor, is approved for the treatment of human disease (acute myeloid leukemia) [28]. Therefore, future studies are needed to estimate the risks and benefits of anti-PKC therapy to regulate αKlotho.
PKC-activating phorbol esters including PMA are cancerogenic due to the multiple tumor-promoting cellular effects of PKC [21, 45]. In our study, PMA lowered expression of potent tumor suppressor αKlotho, an effect which may also be relevant for the cancer-promoting effects of PKC activators.
It has to be kept in mind that our study is solely based on cell culture experiments involving two different kidney cell lines. Future studies are needed to decipher the significance of PKC for αKlotho regulation in vivo.
In summary, our study uncovers PKC activity as a potent negative regulator of αKlotho gene expression in MDCK and NRK-52E cells with PKCγ having a pivotal role for this effect in the two cell lines. PKC-dependent suppression of αKlotho may be relevant for heart and kidney disease as well as cancer progression.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Bacchetta J, Sea JL, Chun RF et al (2013) Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 28:46–55. https://doi.org/10.1002/jbmr.1740
Bär L, Hase P, Föller M (2019) PKC regulates the production of fibroblast growth factor 23 (FGF23). PLoS One 14:e0211309. https://doi.org/10.1371/journal.pone.0211309
Bergwitz C, Jüppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61:91–104. https://doi.org/10.1146/annurev.med.051308.111339
Bi X, Yang K, Zhang B et al (2020) The protective role of Klotho in CKD-associated cardiovascular disease. Kidney Dis (Basel) 6:395–406. https://doi.org/10.1159/000509369
Blau JE, Collins MT (2015) The PTH-vitamin D-FGF23 axis. Rev Endocr Metab Disord 16:165–174. https://doi.org/10.1007/s11154-015-9318-z
Braz JC, Gregory K, Pathak A et al (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248–254. https://doi.org/10.1038/nm1000
Caino MC, von Burstin VA, Lopez-Haber C et al (2011) Differential regulation of gene expression by protein kinase C isozymes as determined by genome-wide expression analysis. J Biol Chem 286:11254–11264. https://doi.org/10.1074/jbc.M110.194332
Carpinelli MR, Wise AK, Burt RA (2011) Vitamin D-deficient diet rescues hearing loss in Klotho mice. Hear Res 275:105–109. https://doi.org/10.1016/j.heares.2010.12.009
Chu C, Elitok S, Zeng S et al (2021) C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival. BMC Nephrol 22:125. https://doi.org/10.1186/s12882-021-02329-7
Dempsey EC, Newton AC, Mochly-Rosen D et al (2000) Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279:L429–L438. https://doi.org/10.1152/ajplung.2000.279.3.L429
Deshmukh M, Johnson EM (2000) Staurosporine-induced neuronal death: multiple mechanisms and methodological implications. Cell Death Differ 7:250–261. https://doi.org/10.1038/sj.cdd.4400641
Di Giuseppe R, Kühn T, Hirche F et al (2015) Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study. Eur J Epidemiol 30:131–141. https://doi.org/10.1007/s10654-014-9982-4
Di Zou WW, He Y et al (2018) The role of klotho in chronic kidney disease. BMC Nephrol 19:285. https://doi.org/10.1186/s12882-018-1094-z
Doi S, Zou Y, Togao O et al (2011) Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286:8655–8665. https://doi.org/10.1074/jbc.M110.174037
Donate-Correa J, Martín-Núñez E, Mora-Fernández C et al (2015) Klotho in cardiovascular disease: current and future perspectives. World J Biol Chem 6:351–357. https://doi.org/10.4331/wjbc.v6.i4.351
Dowling CM, Hayes SL, Phelan JJ et al (2017) Expression of protein kinase C gamma promotes cell migration in colon cancer. Oncotarget 8:72096–72107. https://doi.org/10.18632/oncotarget.18916
Ewendt F, Feger M, Föller M (2020) Role of fibroblast growth factor 23 (FGF23) and αKlotho in cancer. Front Cell Dev Biol 8:601006. https://doi.org/10.3389/fcell.2020.601006
Guo Y, Zhuang X, Huang Z et al (2018) Klotho protects the heart from hyperglycemia-induced injury by inactivating ROS and NF-κB-mediated inflammation both in vitro and in vivo. Biochim Biophys Acta Mol Basis Dis 1864:238–251. https://doi.org/10.1016/j.bbadis.2017.09.029
Haruna Y, Kashihara N, Satoh M et al (2007) Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A 104:2331–2336. https://doi.org/10.1073/pnas.0611079104
Haussler MR, Whitfield GK, Kaneko I et al (2012) The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 13:57–69. https://doi.org/10.1007/s11154-011-9199-8
He H, Davidson AJ, Wu D et al (2010) Phorbol ester phorbol-12-myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells. Prostate 70:1119–1126. https://doi.org/10.1002/pros.21146
He Q, Shumate LT, Matthias J et al (2019) A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23. JCI Insight 4. https://doi.org/10.1172/jci.insight.125007
Hu MC, Shi M, Moe OW (2019) Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters. Pflugers Arch 471:99–108. https://doi.org/10.1007/s00424-018-2238-5
Imai M, Ishikawa K, Matsukawa N et al (2004) Klotho protein activates the PKC pathway in the kidney and testis and suppresses 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression. Endocrine 25:229–234. https://doi.org/10.1385/ENDO:25:3:229
Isakov N (2018) Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol 48:36–52. https://doi.org/10.1016/j.semcancer.2017.04.012
Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378. https://doi.org/10.1038/ki.2011.47
Kaleli HN, Ozer E, Kaya VO et al (2020) Protein kinase C isozymes and autophagy during neurodegenerative disease progression. Cells 9:553. https://doi.org/10.3390/cells9030553
Kawano T, Inokuchi J, Eto M et al (2021) Activators and inhibitors of protein kinase C (PKC): their applications in clinical trials. Pharmaceutics 13. https://doi.org/10.3390/pharmaceutics13111748
Kim J-H, Park EY, Hwang K-H et al (2021) Soluble αKlotho downregulates Orai1-mediated store-operated Ca2+ entry via PI3K-dependent signaling. Pflugers Arch 473:647–658. https://doi.org/10.1007/s00424-020-02510-1
Kim W-Y, Lee G-S, Kim Y-H et al (2007) Immunolocalization of protein kinase C isoenzymes α, βI, βII and γ in adult and developing rat kidney. Electrolyte Blood Press 5:75–88. https://doi.org/10.5049/EBP.2007.5.2.75
Kolczynska K, Loza-Valdes A, Hawro I et al (2020) Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review. Lipids Health Dis 19:113. https://doi.org/10.1186/s12944-020-01286-8
Kuro-o M (2010) A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mech Ageing Dev 131:270–275. https://doi.org/10.1016/j.mad.2010.02.008
Kuro-o M (2010) Klotho. Pflugers Arch 459:333–343. https://doi.org/10.1007/s00424-009-0722-7
Kuro-o M (2012) Klotho in health and disease. Curr Opin Nephrol Hypertens 21:362–368. https://doi.org/10.1097/MNH.0b013e32835422ad
Kuro-o M (2019) The Klotho proteins in health and disease. Nat Rev Nephrol 15:27–44. https://doi.org/10.1038/s41581-018-0078-3
Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51. https://doi.org/10.1038/36285
Kurosu H, Yamamoto M, Clark JD et al (2005) Suppression of aging in mice by the hormone Klotho. Science 309:1829–1833. https://doi.org/10.1126/science.1112766
Lee EY, Kim SS, Lee J-S et al (2014) Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One 9:e102984. https://doi.org/10.1371/journal.pone.0102984
Li J, Gobe G (2006) Protein kinase C activation and its role in kidney disease. Nephrology (Carlton) 11:428–434. https://doi.org/10.1111/j.1440-1797.2006.00673.x
Lin W, Li Y, Chen F et al (2017) Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice. Sci Rep 7:46195. https://doi.org/10.1038/srep46195
Liu M, Clarke CJ, Salama MF et al (2017) Co-ordinated activation of classical and novel PKC isoforms is required for PMA-induced mTORC1 activation. PLoS One 12:e0184818. https://doi.org/10.1371/journal.pone.0184818
Liu Q-F, Ye J-M, Yu L-X et al (2018) Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease. J Investig Med 66:669–675. https://doi.org/10.1136/jim-2017-000560
Maekawa Y, Ishikawa K, Yasuda O et al (2009) Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 35:341–346. https://doi.org/10.1007/s12020-009-9181-3
Maltese G, Psefteli P-M, Rizzo B et al (2017) The anti-ageing hormone klotho induces Nrf2-mediated antioxidant defences in human aortic smooth muscle cells. J Cell Mol Med 21:621–627. https://doi.org/10.1111/jcmm.12996
Montesano R, Orci L (1985) Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42:469–477. https://doi.org/10.1016/0092-8674(85)90104-7
Morishita K, Shirai A, Kubota M et al (2001) The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 131:3182–3188. https://doi.org/10.1093/jn/131.12.3182
Münz S, Wolf L, Hoelzle LE et al (2022) Impact of cytotoxic agents or apoptosis stimulants on αklotho in MDCK, NRK-52E and HK2 kidney cells. Aging (Albany NY) 14:7282–7299. https://doi.org/10.18632/aging.204238
Noh H, King GL (2007) The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl:S49–S53. https://doi.org/10.1038/sj.ki.5002386
Ohnishi M, Razzaque MS (2010) Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 24:3562–3571. https://doi.org/10.1096/fj.09-152488
Olejnik A, Franczak A, Krzywonos-Zawadzka A et al (2018) The biological role of Klotho protein in the development of cardiovascular diseases. Biomed Res Int 2018:5171945. https://doi.org/10.1155/2018/5171945
Perwad F, Zhang MYH, Tenenhouse HS et al (2007) Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293:F1577–F1583. https://doi.org/10.1152/ajprenal.00463.2006
Pillai P, Desai S, Patel R et al (2011) A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. Int J Biochem Cell Biol 43:784–794. https://doi.org/10.1016/j.biocel.2011.02.002
Rausch S, Föller M (2022) The regulation of FGF23 under physiological and pathophysiological conditions. Pflugers Arch 474:281–292. https://doi.org/10.1007/s00424-022-02668-w
Razzaque MS, Lanske B (2007) The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194:1–10. https://doi.org/10.1677/JOE-07-0095
Razzaque MS, Sitara D, Taguchi T et al (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20:720–722. https://doi.org/10.1096/fj.05-5432fje
Saito N, Shirai Y (2002) Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J Biochem 132:683–687. https://doi.org/10.1093/oxfordjournals.jbchem.a003274
Singh RM, Cummings E, Pantos C et al (2017) Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev 22:843–859. https://doi.org/10.1007/s10741-017-9634-3
Stone RM, Weber BL, Spriggs DR et al (1988) Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 72:739–744
Suzuki Y, Kuzina E, An SJ et al (2020) FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho. Proc Natl Acad Sci U S A 117:31800–31807. https://doi.org/10.1073/pnas.2018554117
Tahara E, Kadara H, Lacroix L et al (2009) Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 8:801–807. https://doi.org/10.4161/cbt.8.9.8186
Tamaoki T, Nomoto H, Takahashi I et al (1986) Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun 135:397–402. https://doi.org/10.1016/0006-291x(86)90008-2
Taneike M, Nishida M, Nakanishi K et al (2021) Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure. Sci Rep 11. https://doi.org/10.1038/s41598-021-81517-9
Tang X, Wang Y, Fan Z et al (2016) Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma. Lab Invest 96:197–205. https://doi.org/10.1038/labinvest.2015.86
Teng B, Duong M, Tossidou I et al (2014) Role of protein kinase C in podocytes and development of glomerular damage in diabetic nephropathy. Front Endocrinol (Lausanne) 5:179. https://doi.org/10.3389/fendo.2014.00179
Tsao H-K, Chiu P-H, Sun SH (2013) PKC-dependent ERK phosphorylation is essential for P2X7 receptor-mediated neuronal differentiation of neural progenitor cells. Cell Death Dis 4:e751. https://doi.org/10.1038/cddis.2013.274
Typiak M, Piwkowska A (2021) Antiinflammatory actions of Klotho: implications for therapy of diabetic nephropathy. Int J Mol Sci 22. https://doi.org/10.3390/ijms22020956
Urabe A, Doi S, Nakashima A et al (2021) Klotho deficiency intensifies hypoxia-induced expression of IFN-α/β through upregulation of RIG-I in kidneys. PLoS One 16:e0258856. https://doi.org/10.1371/journal.pone.0258856
Usuda J, Ichinose S, Ishizumi T et al (2011) Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery. Lung Cancer 74:332–337. https://doi.org/10.1016/j.lungcan.2011.03.004
Voelkl J, Alesutan I, Leibrock CB et al (2013) Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 123:812–822. https://doi.org/10.1172/JCI64093
Ward NE, O'Brian CA (1992) Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates. Mol Pharmacol 41:387–392
Wolf I, Levanon-Cohen S, Bose S et al (2008) Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094–7105. https://doi.org/10.1038/onc.2008.292
Xie J, Cha S-K, An S-W et al (2012) Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 3:1238. https://doi.org/10.1038/ncomms2240
Yuan Q, Ren Q, Li L et al (2022) A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling. Nat Commun 13:438. https://doi.org/10.1038/s41467-022-28096-z
Zeldich E, Chen C-D, Colvin TA et al (2014) The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem 289:24700–24715. https://doi.org/10.1074/jbc.M114.567321
Zhou L, Li Y, Zhou D et al (2013) Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol 24:771–785. https://doi.org/10.1681/ASN.2012080865
Zhou Q, Lin S, Tang R et al (2010) Role of Fosinopril and Valsartan on Klotho gene expression induced by angiotensin II in rat renal tubular epithelial cells. Kidney Blood Press Res 33:186–192. https://doi.org/10.1159/000316703
Zhou X, Fang X, Jiang Y et al (2017) Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma. J Hematol Oncol 10:37. https://doi.org/10.1186/s13045-017-0391-5
Acknowledgements
The authors thank S. Münz, H. Fross, and A. Ullrich for support.
Funding
Open Access funding enabled and organized by Projekt DEAL. This study was supported by Deutsche Forschungsgemeinschaft (Fo695/2-2).
Author information
Authors and Affiliations
Contributions
MF designed the research. LW, JV, JA and MFe performed the experiments and analyzed the data, LW, JV and DM made statistical analysis, LW, JV and MF wrote the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.
Consent for publication
All authors approved the publication.
Competing interests
The authors declare no competing interests.
Human and animal ethics
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wolf, L., Vogt, J., Alber, J. et al. PKC regulates αKlotho gene expression in MDCK and NRK-52E cells. Pflugers Arch - Eur J Physiol 476, 75–86 (2024). https://doi.org/10.1007/s00424-023-02863-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00424-023-02863-3